10.7
Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comp…
In vitro–in vivo correlation is a predictive mathematical model demonstrating the relationship between in vitro drug properties and a relevant in vivo response.
The correlation is defined at three levels.
Level A correlation represents a point-to-point correlation between in vitro dissolution and in vivo absorption, justifying manufacturing and formulation changes without additional human studies.
Level B correlation utilizes statistical moment analysis to compare the mean in vitro dissolution time to the mean in vivo dissolution. Still, this correlation method alone cannot justify manufacturing changes, formulation modification, and batch-to-batch quality.
Level C correlation relates one dissolution time point to one pharmacokinetic parameter and helps develop formulations.
Multiple level C correlation links one or multiple pharmacokinetic parameters to the drug quantity dissolved at different time intervals.
In a study with three sustained-release aspirin products, the dissolution times were linearly correlated to absorption times, indicating the dependence of aspirin’s rapid absorption on the dissolution rate.
View the full transcript and gain access to JoVE Core videos
Q1: What is in vitro–in vivo correlation and why is it important in drug development?
In vitro–in vivo correlation (IVIVC) is a predictive mathematical model demonstrating the relationship between in vitro drug properties and in vivo response. IVIVC reduces costly in vivo studies, establishes meaningful dissolution specifications, and decreases regulatory burden. A meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while ensuring batch-to-batch consistency and validating dissolution specifications based on in vivo performance.
Q2: How do Level A, B, and C correlations differ in IVIVC?
Level A correlation represents point-to-point correlation between in vitro dissolution and in vivo absorption, justifying manufacturing and formulation changes without additional human studies. Level B uses statistical moment analysis comparing mean dissolution times but cannot justify manufacturing changes alone. Level C relates one dissolution time point to one pharmacokinetic parameter and helps develop formulations. Multiple Level C correlations link one or multiple pharmacokinetic parameters to drug quantity dissolved at different time intervals.
Q3: What is the relationship between dissolution rate and drug absorption?
Dissolution rate directly influences absorption rate and plasma drug appearance. A faster dissolution rate leads to quicker drug appearance in plasma. In a study of three sustained-release aspirin products, dissolution times were linearly correlated to absorption times, indicating aspirin's rapid absorption depends on dissolution rate. This relationship demonstrates how formulations with different dissolution rates cause differences in serum drug concentration.
Q4: How does IVIVC reduce the need for human bioavailability studies?
The main objective of developing IVIVC is establishing the dissolution test as a substitute for in vivo bioavailability studies in humans. By establishing linear relationships between in vitro dissolution and in vivo bioavailability parameters, IVIVC enables predictive modeling. This approach facilitates clinically relevant drug product specifications methods of establishment while ensuring batch-to-batch consistency and aiding in new dosage form development without repeated human testing.
Q5: What role does the biopharmaceutic classification system play in IVIVC?
The biopharmaceutic drug classification system (BCS) provides a predictive approach relating physicochemical characteristics of drug substances and products to in vivo bioavailability, particularly for immediate-release oral drug products. BCS Class I drugs meet specific criteria enabling predictive IVIVC development. This classification system helps optimize pharmaceutical product performance by connecting drug properties to expected bioavailability outcomes in clinical settings.
Q6: What are the key applications of establishing IVIVC in pharmaceutical development?
IVIVC applications include ensuring batch-to-batch consistency, aiding in new dosage form development, and validating dissolution specifications based on in vivo performance. Two key approaches involve establishing linear relationships between in vitro dissolution and in vivo bioavailability parameters, and modifying dissolution methodology using previous bioavailability data. These applications enable cost-effective formulation optimization while maintaining product quality and regulatory compliance.
Q7: How does serum drug concentration correlate with in vitro dissolution?
The correlation of serum drug concentration with the percent of drug dissolved highlights the interplay between in vitro dissolution and in vivo absorption. Various formulations with different dissolution rates produce differences in serum drug concentration profiles. Understanding this relationship is pivotal in optimizing pharmaceutical product performance and ensuring efficacy in clinical settings through predictive IVIVC modeling.